GSK’s drops chronic cough drug, dampening $2bn Bellus Health bid
The British pharma company will discontinue camlipixant’s late-stage RCC programme, though it will continue the drug’s development in two forms of IBS.
20 July 2026
20 July 2026
The British pharma company will discontinue camlipixant’s late-stage RCC programme, though it will continue the drug’s development in two forms of IBS.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.